Sydney biotech company moves from the development of proteomics technologies to commercialization of its first instruments in the world market proteomics. The case study highlights a number of activities involving the 120-person company, the internal problems of Proteome systems cost as it moves towards commercialization of its technology, and how it solves these problems. In the long term, Proteome Systems wants to be a drug discovery company, and now, at the end of 2003, the Director General is considering buying U.S. drug discovery company Proteome Systems to improve their own products-discovery efforts. "Hide
by Jonathan West, Mona Ashiya Source: Harvard Business School 30 pages. Publication Date: November 24, 2003. Prod. #: 604049-PDF-ENG
Related Case Solutions & Analyses:
Trade Restrictions and Hong Kongs Textiles and Clothing Industry
Nectar: Making Loyalty Pay
Motorcowboy: Getting a Foot in the Door B
Currency Crises in the United Kingdom and Hong Kong
Don Jenkins: Resigning from the Firm
Paperless Healthcare: Progress and Challenges of an IT-Enabled Healthcare System
THE WALT DISNEY COMPANY AND PIXAR INCTO ACQUIRE OR NOT TO ACQUIRE
AQUALISA QUARTZ: SIMPLY A BETTER SHOWER
General Electric after GE Capital
AutoZone
